AKT1 and colorectal cancer: such as triple-negative breast or KRas mutant colorectal cancers have shown additive cytotoxicity or reversal of resistance when MEK inhibitors have been combined with inhibitors of the PI3K-AKT-mTOR pathway [4,7].